INTRODUCTION
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
is the world's premier meeting on infectious diseases and antimicrobial agents,
organized by the American Society for Microbiology. This Brief discusses some of
the keynote lectures at the 42nd ICAAC 2002, focusing on emerging and
re-emerging infections and the increasing threat of bioterrorism.
SCOPE OF THIS REPORT
- The key pathogens and bioterrorism threats are identified. Incentives for
developing new products for biodefense are discussed.
- Emerging and re-emerging infections are profiled. Key commercial
opportunities to develop and commercialize relevant products are identified.
REPORT HIGHLIGHTS
The bioterrorism-related pharmaceutical market can offer potential benefits
for smaller niche players. Whilst the potential for blockbusters is limited,
government grants can lead to assured revenues, without the need for extensive
detailing activities. In addition, the publicity surrounding platform
technologies arising from government purchase of such products can give a major
boost to small players at minimal cost.
The low incidence of rare and emerging infectious diseases, such as West Nile
disease, present market opportunities for prophylactics, if not for novel
therapeutics. Given the probable reluctance of government agencies to reimburse
prophylactic products in non-risk groups, there is potential to introduce
schemes such as co- or full- patient payment.
KEY REASONS TO BUY THIS REPORT
- Identify the commercial potential of entering into biodefense and emerging
disease niche markets
- Understand how compulsory licensing could act as a major disincentive to
expanding the indication of existing products to meet bioterrorist threats.
View Cart
